IRONMAN is a registry for men with advanced prostate cancer that collects information about a man’s prostate cancer, their treatment, and what side effects they may be experiencing.

Over a period of five years, the Registry will seek to enroll at least 5,000 men with advanced prostate cancer across 10 countries, in order to better understand what causes prostate cancer, its biological markers, how to stop or slow its progression, and how to provide the best possible
care to enable men to live the best quality life possible.

WHY IS THIS REGISTRY IMPORTANT?

More than 366,000 men die of prostate cancer globally every year. New treatments and therapies are being prescribed, but we are yet to understand which of these are delivering the best outcomes for men with advanced prostate cancer.

Joining IRONMAN and participating in this study can help us understand more about your particular type of prostate cancer and your overall health.

GOALS OF THE STUDY

The Registry seeks to improve the lives of men with advanced
prostate cancer by:
• Discovering which treatments work best in the real world,
for real people.
• Identifying which treatments or combinations of treatments are
associated with the highest rates of survival and quality of life.
• Determining if treatments are associated with side effects
and other diseases or conditions.
• Developing a collection of blood samples to allow research
on different types of prostate cancer.
• Creating an international partnership to work together
and identify what men with advanced prostate cancer
need most to thrive

WHAT WILL BE REQUIRED OF YOU AS A PARTICIPANT?

If you agree to participate in this study, we will collect:
• Patient medical history
• Treatment information
• Blood samples
We’ll also send health surveys to you so we can measure
your quality of life over time.

ELIGIBILITY CRITERION

You may be eligible to participate if you have the following types
of prostate cancer:

1. Metastatic Hormone Sensitive Prostate Cancer (mHSPC):
If your cancer has spread to other parts of the body,
you have not received hormonal therapy called androgen
deprivation therapy (ADT), or you have received ADT for
a short amount of time.

2. Castration Resistant Prostate Cancer (CRPC):
If your cancer is growing despite having a low testosterone
level from treatments in the past.
If you’re not sure about your eligibility, consult your doctor
or healthcare team.